How do I discuss the Gleason score with a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Discuss the Gleason Score with a Patient

When discussing the Gleason score with a patient, focus on explaining it as a measure of cancer aggressiveness that guides treatment decisions and helps predict outcomes. 1

Explaining the Basics of the Gleason Score

  • The Gleason score is determined by a pathologist who examines prostate tissue samples under a microscope to evaluate how much the cancer cells differ from normal prostate cells 1
  • Explain that the score is calculated by adding the grades of the two most common cancer patterns seen in the biopsy, with each pattern scored from 1 to 5 2, 1
  • Clarify that Gleason scores range from 6 to 10 in clinical practice, with higher scores indicating more aggressive cancer cells 1
  • Mention that Gleason scores of 2 to 4 are uncommon, and most detected tumors range from 5 to 10 2

Breaking Down the Gleason Score Ranges

  • Gleason score 6 (3+3): Describe as well-differentiated cancer cells that look similar to normal cells and tend to grow slowly 1, 3
  • Gleason score 7: Explain the important distinction between 3+4 and 4+3 patterns:
    • 3+4: Moderately differentiated cancer with better prognosis than 4+3 4
    • 4+3: More aggressive form with worse outcomes than 3+4 4
  • Gleason scores 8-10: Describe as poorly differentiated cancer cells that look very different from normal cells and tend to grow more rapidly 1, 5

Explaining Risk Stratification

  • Show how the Gleason score contributes to risk categorization along with PSA level and clinical stage 2:
    • Low risk: PSA ≤ 10 ng/mL and Gleason score of 6 or less and clinical stage T1c or T2a 2
    • Intermediate risk: PSA 10 to 20 ng/mL or Gleason score of 7 or clinical stage T2b 2
    • High risk: PSA > 20 ng/mL or Gleason score of 8 to 10 or clinical stage T2c 2

Discussing Treatment Implications

  • Explain that with each increase in Gleason score, there is an increase in cancer aggressiveness, which influences treatment recommendations 2
  • For Gleason score 6: Active surveillance may be appropriate for many patients 1
  • For Gleason score 7: Treatment options may include surgery or radiation, depending on other factors 4
  • For Gleason scores 8-10: More aggressive treatment approaches are typically recommended 5

Communication Tips

  • Use simple language and visual aids when explaining the scoring system 1
  • Avoid medical jargon and explain that the Gleason score is just one factor in treatment decision-making 2
  • Acknowledge the anxiety that can come with cancer diagnosis and provide reassurance about treatment options 2
  • For minimal tumor findings on biopsy, explain that the assigned Gleason score may have limitations in predicting outcomes 6
  • Emphasize that even Gleason score 6 cancers are still malignant, though they typically have an excellent prognosis with appropriate management 3

Important Caveats

  • When discussing minimal cancer on biopsy (less than 1 mm or 5% of one core), explain that the Gleason score may be less reliable in predicting final pathology 6
  • For patients with tertiary patterns (a small component higher than the two main patterns), explain how this might affect prognosis 2
  • Clarify that the Gleason score at initial diagnosis may not reflect the current state of metastatic disease if the cancer has progressed 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.